Quick take on some upcoming catalysts

With Gilead’s (NASDAQ: GILD) recent announcement about the 7977 data(100% RVR, 25/25 in genotype 1 patients so far) should have Idenix(NASDAQ: IDIX) and Achillion(NASDAQ: ACHN) investors thinking hard about the relative risk-reward at this point. GILD announced that data would be available at CROI12 on March 5th-8th; they plan to annouce more SVR data on […]

Trade Ideas for some upcoming catalysts

We wanted to throw out some trading ideas for some stocks that we are following, but may not necessarily get full write-ups on in time. Ideally, we will have research pieces on some of the companies below in the near future. – On Thursday January 26th, Celgene(NASDAQ:CELG) will be reporting earnings and financial guidance for […]

AMLN – Neutral/Bearish Trade for PDUFA

Analyst Notes: These kind of things are troubling because of the cardiovascular nature of the FDA’s qualms. However, give it a 50% success probability “In the second CRL, Amylin and its partners were asked to conduct a thorough QT (tQT) study with Bydureon and submit data from the DURATION-5 study which was conducted to compare […]

ACHN & ARIA – Time To Take Some Profits

Both Achillion and Ariad hit 52-week highs today after running up on positive news. While we continue to believe the companies will be successful, we also believe the stocks are getting fairly expensive and think it is a good time to take profits. Since recommending ARIA on November 10th at $10.72, it has gained 31.25% […]

ONXX – Trade Idea

Onyx Pharmaceuticals(ONXX) submitted their NDA for Carfilzomib to the FDA under the accelerated approval process on 9/28/11 and are seeking a 6-month priority review. At the earliest, they could be hearing back from the FDA on Saturday, November 26th. Typically, the FDA will notify the sponsoring company within 60 days as to whether or not […]

ALIM & PSDV – Trade Review

We fully expected that pSivida(NASDAQ: PSDV) and Alimera Sciences(NASDAQ:ALIM) will receive another Complete Response Letter for ILUVIEN in the treatment of diabetic macular edema (DME). We see little reason for the FDA to approve this NDA, based on the safety and efficacy data. Both PSDV and ALIM will be hard up for cash if ILUVIEN […]

INHX – Trade Idea

Video: http://content.screencast.com/users/biotechtraderHB/folders/Default/media/e7f5888c-ae53-412d-ad9e-36eee29a425b/$INHX110911.swf Analyst Notes: INHX showed only 7 day viral reduction data, which has not been shown to be highly correlated to a sustained viral response. What we want to see are 4 week results demonstrating high rates of rapid virologic response, or undetectable levels of viral rna. 4 week data is highly predictive of […]